POSB270 Does Orphan Drug Status Confer Any Benefits for Products Undergoing HTA Appraisal By NICE in England?

Abstract

Authors

G Foxon P Craddy C Wilson

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×